S3648

The Immediate Access for the Terminally Ill Act (S.3648), introduced on January 15, 2026, seeks to amend Title II of the Social Security Act. Its primary objective is to allow individuals with incurable terminal illnesses, as defined by the Compassionate Allowance list, to receive Social Security Disability Insurance (SSDI) benefits without the standard waiting period. The bill also explicitly prohibits the concurrent receipt of disability insurance benefits and unemployment insurance. Currently, the bill has been referred to the Senate Committee on Finance, indicating it is in the early stages of the legislative process. This bill does not authorize new funding but rather modifies the timing and eligibility rules for existing Social Security Disability Insurance benefits. The mechanism involves the Social Security Administration (SSA) establishing and updating a list of qualifying medical conditions. The financial impact would be a shift in the timing of benefit payouts for a specific, already-eligible population, rather than an increase in the total amount of benefits paid over the lifetime of the recipient. The prohibition on concurrent benefits clarifies existing policy and aims to prevent double-dipping from federal programs. From a market perspective, the direct impact on publicly traded companies is expected to be neutral to slightly administrative. Health insurance providers such as UnitedHealth Group, CVS Health ($CVS) (via Aetna), Humana ($HUM), Cigna Group ($CI), and Molina Healthcare ($MOH) may see minor adjustments in claims processing or actuarial models for their disability insurance offerings or for managing member populations who may also be receiving federal disability benefits. The bill does not create new revenue streams or impose significant new costs on these companies. The presidential memorandum on energy and infrastructure is unrelated to this bill's policy area. Given its early stage, the bill faces a lengthy legislative path. Referral to the Senate Committee on Finance is the first step, and it would need to be approved by this committee, then passed by the full Senate, and subsequently passed by the House of Representatives (potentially with its companion bill HR7104), before being sent to the President for signature. The presence of a companion bill (HR7104) in the House indicates bipartisan or bicameral interest, which can improve legislative momentum.